Shopping Cart
- Remove All
- Your shopping cart is currently empty
OA-Br-1 is an orally active, selective inhibitor of PTP1B with an IC50 value of 7.08 μM. It induces apoptosis and exhibits broad-spectrum anti-cancer cell proliferation activity. OA-Br-1 exerts anti-breast cancer effects both in vitro and in vivo through the PTP1B/PI3K/AKT signaling pathway.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | OA-Br-1 is an orally active, selective inhibitor of PTP1B with an IC50 value of 7.08 μM. It induces apoptosis and exhibits broad-spectrum anti-cancer cell proliferation activity. OA-Br-1 exerts anti-breast cancer effects both in vitro and in vivo through the PTP1B/PI3K/AKT signaling pathway. |
In vitro | OA-Br-1 exhibits strong inhibitory activity against PTP1B with an IC50 value of 7.08 μM, while its inhibitory effect on TCPTP is weaker, with an IC50 of 222.28 μM [1]. It inhibits the proliferation of breast cancer cells (MCF-7, MDA-MB-231, MDA-MB-453) in a concentration- and time-dependent manner, with IC50 values of 8.76, 18.13, and 22.34 μM at 72 hours, respectively [1]. OA-Br-1 (5-30 μM; 48 h) induces apoptosis in MCF-7 and MDA-MB-231 cells [1] and increases the thermal stability of PTP1B [1]. Additionally, OA-Br-1 reduces colony formation in these cells dose-dependently [1] and decreases protein levels of p-PI3K and p-AKT, indicating its antitumor activity through the PTP1B/PI3K/AKT pathway in breast cancer cells [1]. |
In vivo | OA-Br-1 (30-60 mg/kg; oral administration; daily) exhibits antitumor effects in a BALB/c female nude mouse model with subcutaneously implanted MCF-7 cells by inhibiting the PTP1B/PI3K/AKT signaling pathway [1]. |
Alias | OA-Br-1, 3-O-(6-Bromo-D-mannosyl)-28-acylamino-n-caproate methyl oleanolic acid |
Molecular Weight | 808.92 |
Formula | C43H70BrNO8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.